Recent developments in pertussis

Natasha Crowcroft*, Richard Pebody

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

195 Citations (Scopus)

Abstract

Pertussis causes nearly 300 000 deaths in children every year. Most deaths take place in developing countries, but the infection remains a priority everywhere. Pertussis vaccination protects infants and children against death and admission to hospital, but breakthrough disease in vaccinated people can happen. In high-mortality countries, the challenge is to improve timeliness and coverage of childhood vaccination and surveillance. In regions with low mortality and highest coverage, pertussis is frequently the least well-controlled disease in childhood vaccination programmes. Some countries have reported a rise in pertussis in adolescents, adults, and pre-vaccination infants, but how much these changes are real or a result of improved recognition and surveillance remains uncertain. In response, several countries have introduced adolescent and adult acellular pertussis vaccine boosters. The effect so far is unknown; assessment is impeded by poor data. Uncertainties still persist about key variables needed to model and design vaccination programmes, such as risk of transmission from adults and adolescents to infants. New vaccination strategies under investigation include vaccination of neonates, family members, and pregnant women.

Original languageEnglish
Pages (from-to)1926-1936
Number of pages11
JournalThe Lancet
Volume367
Issue number9526
DOIs
Publication statusPublished - 10 Jun 2006

Fingerprint

Dive into the research topics of 'Recent developments in pertussis'. Together they form a unique fingerprint.

Cite this